By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

The Power of Conversations Between Physicians and Patients
Nursing Shortage or Nursing Surplus?
The Future of Consumer-Directed Health Care
Patient Activation and the End of Health Insurance Companies
Passing Hope in the Form of a Baton

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

language barriers in healthcare
Language Barriers Are Most Underestimated Risk in Healthcare
Global Healthcare Policy & Law
March 29, 2026
nurse checking her schedule
Managing On-Call Lists for Healthcare Open Shifts
Health
March 26, 2026
outdoor yoga class in sunny park setting
Resveratrol Capsules VS Resveratrol Powder: Are There Differences?
Health
March 26, 2026
Clinical Trials Demystified: Yousuf A. Gaffar, M.D’s Guide to Research and Patient Impact
Clinical Trials Demystified: Yousuf A. Gaffar, M.D’s Guide to Research and Patient Impact
Health
March 25, 2026

You Might also Like

Swiss Investors Going Direct, Avoiding Funds

May 3, 2011

FDA Has a Good Idea; Doctors Object

May 4, 2012
Image
eHealthFinanceHospital AdministrationTechnologyWellness

How Budget Cuts are Affecting Mental Health Care

September 22, 2016

The Threat to Legalized Cannabis

October 9, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?